Valuation : Sutro Biopharma, Inc.

Market Cap 280M 241M 228M 207M 388M 26.71B 390M 2.71B 1.04B 13.59B 1.05B 1.03B 42.94B P/E 2026 *
-2.05x
P/E 2027 * -2.55x
Enterprise Value 280M 241M 228M 207M 388M 26.71B 390M 2.71B 1.04B 13.59B 1.05B 1.03B 42.94B EV / Sales 2026 *
5.42x
EV / Sales 2027 * 8.85x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * -
1 day-5.44%
1 week-15.99%
Current month-16.70%
1 month-20.85%
3 months-41.46%
6 months-31.04%
Current year+45.72%
1 week 16.48
Extreme 16.48
19.76
1 month 16.48
Extreme 16.48
23.45
Current year 10.15
Extreme 10.15
43.85
1 year 7.15
Extreme 7.15
43.85
3 years 5.23
Extreme 5.231
61.3
5 years 5.23
Extreme 5.231
237
10 years 5.23
Extreme 5.231
283
Manager TitleAgeSince
Chief Executive Officer 55 13/03/2025
Director of Finance/CFO 53 02/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Director/Board Member 70 01/08/2009
Director/Board Member 67 01/02/2017
Director/Board Member 51 25/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
2/6/26 Exercice

Chief Financial Officer

5,000 0.0302%
4/3/26 Exercice

Chief Administrative Officer

1,627 0.0099%
4/3/26 Exercice

Chief Executive Officer

1,858 0.0113%
Change 5-day change 1-year change 3-year change Capi.($)
-5.44%-15.99%+92.27%-62.86% 280M
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average -0.81%-4.25%+36.81%+216.44% 27.07B
Weighted average by Cap. -0.56%-2.84%+31.32%+170.41%

Financials

2026 *2027 *
Net sales 51.55M 44.42M 42.06M 38.12M 71.52M 4.93B 71.88M 500M 192M 2.51B 194M 189M 7.92B 31.59M 27.22M 25.77M 23.36M 43.83M 3.02B 44.05M 306M 118M 1.54B 119M 116M 4.85B
Net income -130M -112M -106M -95.77M -180M -12.37B -181M -1.25B -483M -6.3B -486M -476M -19.89B -141M -121M -115M -104M -195M -13.45B -196M -1.36B -524M -6.84B -529M -517M -21.61B
Net Debt - -
Logo Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Employees
128
Date Price Change Volume
11/09/26 USD 16.86 -5.44% 942,335
10/09/26 USD 17.83 -2.86% 169,204
09/09/26 USD 18.36 -3.90% 145,605
08/09/26 USD 19.10 -4.83% 153,539
04/09/26 USD 20.07 -2.29% 124,764
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
16.86USD
Average target price
47.23USD
Spread / Average Target
+180.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STRO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!